Investor Presentaiton
PBF
Fluzone High-Dose/Efluelda set the bar high in 60/65+
Outstanding results confirmed in most recent randomized
real-world studies
Driving global expansion
Objective
Design
DANFLU-11
Impact of QIV HD vs SD on
pneumonia and influenza
(P&I) and other
hospitalizations
Randomized real-world study
12k subjects 65-79
DANFLU-22
Impact of QIV HD vs SD on
P&I and other hospitalizations
Randomized real-world study
Target 208k subjects 65+
Recommendations or
preferential reimbursement in
10+ key markets
Outcome /
next steps
64.4% reduction in P&I
19k randomized to date
hospitalization
Presented at ESC 2022,
accepted in NEJM Evidence
Started in 22/23 season
1. Johansen ND, et al. NEJM Evidence. 2023. 2. Clinicaltrials.gov: NCT05517174.
44 Vaccines Investor Event
sanofiView entire presentation